SEC recommends approval of additional indication for BMS' anti-cancer drug nivolumab: Gireesh Babu, New Delhi Tuesday, November 19, 2024, 08:00 Hrs [IST] The Subject Expert Commit ...

The infusion rate should be reduced by 50% in ... Thus far, the combination of cetuximab and radiation has never been compared with cisplatin-based chemoradiation, which is still considered ...

The infusion rate should be reduced by 50% in ... Thus far, the combination of cetuximab and radiation has never been compared with cisplatin-based chemoradiation, which is still considered ...

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

They are not cross-resistant to cisplatin, 5-fluorouracil or arabinosylcytosine, nor to the tubulin inhibitors taxol and vincristine. Stable resistance in the absence of Et743 for one year ...

with chemotherapy (cisplatin/carboplatin and pemetrexed). BAY 2927088, which combines inhibition of HER2 (including exon 20 insertions and point mutations) with blockade of EGFR, both mutations ...

IV infusion 5 or 10 mg/kg every 14 days in combination ... 15 mg/kg every 3 weeks with paclitaxel and cisplatin, or paclitaxel and topotecan for Stage III or IV ovarian, fallopian tube or ...

It is given in uterus and small cell lung cancer as an IV infusion in a dose of 1.5 mg ... of 0.75 mg/m 2 is given for 3 days along with cisplatin on the first day of a 21-day course.

("KORU Medical" or the "Company"), a leading medical technology company focused on development, manufacturing, and commercialization of innovative and patient-centric large volume subcutaneous ...

Adipo Therapeutics LLC, a late-stage, preclinical biopharmaceutical company developing a potential treatment for obesity and related metabolic disorders, presented data from two studies at the ...

A few months after appointing a new CEO, a drug developer in Research Triangle Park has made more additions to its leadership team. STORY HIGHLIGHTS Fennec Pharmaceuticals appointed three new C ...

Prespecified AEs of special interest for EV were analyzed and reported as composite terms (hyperglycemia, peripheral neuropathy, ocular events [dry eye, corneal disorders, and blurred vision], skin ...